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DOI 10.1016/j.chembiol.2010.02.004With many biotech companies reaching
for commercial success, it helps when
the founding science comes from an
unquestioned leader in the field. Such is
the case with Ancora Pharmaceuticals
(http://www.ancorapharma.com), founded
in 2003 to develop a synthetic carbohy-
drate platform based on work licensed
from MIT. In 2002, the company’s
scientific cofounder, Dr. Peter Seeberger,
a world-class carbohydrate chemist then
based at MIT, helped establish the
company after winning an MIT-based
entrepreneurial competition, setting in
motion the foundation for the now 20
person company based in Medford,
Massachusetts.Ancora’s technology overcomes the labor-intensive nature of
traditional carbohydrate synthesis.Why Carbohydrates?
When seeking to target an infectious
agent, the first place to look is usually
the invading organism’s cell surface,
which is made up of proteins, lipids, and
carbohydrates. For decades, medicine
has been perfecting protein-based ap-
proaches both in drugs and vaccines.
Yet carbohydrates extend well into the
cell’s neighborhood and are often
involved in initial interactions with other
cells and in cell signaling. This makes
them attractive antigens, explaining why
they are of interest for vaccine develop-
ment.
In the vaccine field, perhaps the leading
application for carbohydrate-based ther-
apies to date, many opportunities go
unpursued or are pursued until they reach
a technical hurdle that cannot be over-
come. ‘‘This is mainly due to poor access
to large amounts of homogenous carbo-
hydrate material to work with,’’ explains
Stewart Campbell, Ph.D., Ancora’s vice
president of R&D. However, isolating or
purifying attractive carbohydrate targetsfrom a bacterium, fungus, or other
organism in the quantities needed can
be challenging.
‘‘There are a number of reasons why
carbohydrate synthesis is more attractive
than isolation from the pathogen,’’
explains Geert-Jan Boons, Ph.D., Franklin
Professor of Chemistry, Complex Carbo-
hydrate Research Center, University of
Georgia. Dr. Boons’s lab is focused on
the development of synthetic cancer and
bacterial vaccines. He explains that oligo-
saccharides require conjugation to a
protein for immunization. ‘‘With synthesis,
the conjugation chemistry is much better
because it provides you with an opportu-
nity to attach a linker with unique reactivityso that it can be done in a controlled
fashion,’’ he says. ‘‘Further, with syn-
thesis, you can do really detailed structure
activity relationship studies and thereby
define the most attractive structure for
achieving optimal immunity.’’
Automated carbohydrate synthesis is
one of the remaining frontiers in auto-
mated synthesis technology. This is due
to the carbohydrates’ inherent com-
plexity. Historically, it has been very
difficult to produce homogenous glyco-
proteins using an in vitro technique. ‘‘If
you have bacterial cells, or even mamma-
lian cells, making them, if there is even
a slight change in genetics, they could
start making different glycoforms of the
glycoproteins,’’ explains J. David Warren,
Ph.D., Director, Organic Synthesis Core
Facility, Weill Cornell Medical College.
This can lead to antigenicity and an unin-
tended and undesired immune response
that may not initially be noticeable
because of its subtlety.
‘‘People have shown that differing gly-
coforms can have completely differentChemistry & Biology 17, February 26, 201biological effects,’’ adds Warren. ‘‘One
of the goals of synthetic glycoproteins
would be to have a single glycoform
where you have absolute control over
the form made, thereby eliminating the
need for antigenicity concerns.
Adds Campbell, ‘‘Our carbohydrate
synthesis approach takes away the
uncertainty or inability to attain certain
structures that might be of high biological
interest, but, practically, people have not
been able to access or produce.’’
Synthesis Platform
‘‘We’ve licensed technology in from MIT
and created a lot of know-how to make
the most encompassing carbohydrate
synthesis platform in the world,’’ says
John Pena, Ph.D., Ancora’s president.
‘‘The intellectual property which we
licensed was a unique set of reaction
chemistries and protecting group strate-
gies and linker chemistries that would
allow synthetic chemists to make carbo-
hydrate molecules more time and cost
effectively than had been possible to
date within industry.’’
The initial technology was focused on
a limited set of classes of carbohydrate
molecules. Ancora’s first order was to
prove it had a commercially relevant set
of technologies and develop a more
commercially relevant platform. ‘‘We had
to prove we could make different classes
of carbohydrate structures and that we
could get access to larger amounts/quan-
tities of these structures, so the tech-
nology needs to be scalable,’’ says Pena.
Ancora’s technology overcomes the
labor-intensive nature of traditional car-
bohydrate synthesis. To make polysac-
charides in the laboratory, reactions are
made on a single building block. That
product is purified. You would then do
another glycosylation and go through the
process again. ‘‘This process can take
days, weeks, months to build up a poly-
saccharide,’’ explains Warren. ‘‘With the
technology Ancora has, they can do this0 ª2010 Elsevier Ltd All rights reserved 99
Chemistry & Biology
Innovationsin some cases in a matter of hours or
a day. It really opens the possibilities of
doing this on a large scale.’’ Seeberger
explains that the founding technology
offered an automated oligosaccharide
synthesis platform capable of producing
synthetic carbohydrates about 500 times
faster than previously.
Building Blocks
From a core platform of building blocks
and modification chemistries, Ancora can
make a wide array of structures. Says
Pena, ‘‘We can make 30, 40, 100 mg of
a desired carbohydrate synthetically and
have the chemistries to develop hundreds
of grams or kilograms as required.’’
Ancora realizes that making the core
carbohydrate structures—while essen-
tial—is not the end game. ‘‘We can
make core carbohydrate structures and
then derivitize them very rapidly,’’ says
Pena. The structures can be manipulated
onto proteins, onto glycochips, or onto
a device using linker chemistry or by
modifying the conjugation chemistry as
needed. ‘‘We are able in that way to do
medicinal chemistry or optimization on
a carbohydrate structure which has never
really been done,’’ he says.
Further, Ancora applies their tech-
nology to tease out activity for a polysac-
charide with promising activity for vaccine
development. In some cases, researchers
cannot pinpoint the exact subcomponent
of a sequence or the carbohydrate
epitope that is responsible for activity.
‘‘We make defined fragments syntheti-
cally using our building blocks and
assembly approaches with very defined
sites for conjugation,’’ explains Campbell.
‘‘We then have a series of tools we can
use to evaluate which structures are the
most interesting. We can use glycochips,
where we can put a library of carbohy-
drates on a slide and evaluate which100 Chemistry & Biology 17, February 26, 201ones bind antibodies to the known poly-
saccharide.’’ While binding does not
inherently mean it is going to be func-
tional, it provides some validation that
the carbohydrate structure is at least
partially responsible for the immune
response.
Malaria and Staphylococcus
Ancora’s business model is to develop
synthetic carbohydrate-based vaccines.
They seek to own a piece of the $13
billion global vaccine market that already
includes a few carbohydrate-based
vaccines, including Prevnar, Comvax,
Menactra, and Pneumovax. ‘‘The carbo-
hydrate vaccine is very well commercially
validated,’’ says Pena. Prevnar, launched
in 2002, became the first billion dollar
product in the vaccine field in 2004. ‘‘But
these are made from purified sources,
not synthetically,’’ he adds.
Ancora has two in-house preclinical
vaccine programs and is working with
other companies on others. ‘‘We come
in from a synthetic approach,’’ says
Campbell. ‘‘They are not mixtures, which
is often a problem with purified materials.
They do not have copurifying toxic
contaminants, such as endotoxin-related
molecules, that you would often need
to be rid of when doing purifications.’’
Boons adds that a chemically synthetic
approach is much more effective and
safe, perhaps essential, if the oligosac-
charide of interest derives from a dan-
gerous pathogen, such as anthrax.
The advantages to Ancora’s synthetic
carbohydrate approach are two-fold: (1)
access to previously unattainable struc-
tures expands the opportunity for new
vaccine strategies and (2) the quality of
the material produced allows researchers
to pursue vaccine programs with a repro-
ducible, robust source of materials. ‘‘We
take away the purification variable during0 ª2010 Elsevier Ltd All rights reservedthe early discovery phase when you are
trying to determine exactly what material
to move forward with,’’ says Campbell.
Cell-based carbohydrate antigen expres-
sion can change with the scale and
parameters of the fermentation. What
might be defined as the antigen of interest
at the early discovery, 1-liter fermentation
stage can change when scaled up to a
100-liter fermentor. Surface to volume
ratios change, aeration changes, and the
fermenting organism may respond and
modify the carbohydrate.
Ancora’s malaria vaccine targets the
glycoslyphosphatidylinositol (GPI) class
of carbohydrate. The company also
hopes to develop a carbohydrate-based
preventive vaccine against Staphylo-
coccus, including MRSA, by targeting
another carbohydrate class.Beyond Vaccines
‘‘We look past the vaccine horizon as
well,’’ says Pena, who cites Sanofi Aven-
tis’ Lovenox synthetic antithrombotic as
an example of a carbohydrate-based
drug. Synthetic carbohydrates may also
be important for signaling pathways in
cancer applications or they may play
a role in adhesion events (binding) for
inflammation.
‘‘We believe that what we can do with
carbohydrates helps the rest of the
industry think seriously about carbohy-
drate-based targets and products in
a way they have not been able to before,’’
says Pena. ‘‘They have a lot of different
products they would like to pursue, but
up until now the technology has not
existed to allow it. We fill that void, and
that means more medicines will be avail-
able to help people.’’
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